Abstract
BackgroundPembrolizumab plus lenvatinib is a novel combination with promising efficacy in patients with advanced and recurrent endometrial cancer. This combination demonstrated high objective response rates in a single-arm phase 1b/2...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have